Glaukos/$GKOS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Glaukos
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Ticker
$GKOS
Sector
Trading on
NYSE
Industry
Health Care Equipment & Supplies
Headquarters
Employees
995
ISIN
US3773221029
Website
Glaukos Metrics
BasicAdvanced
$5.4B
-
-$2.27
0.88
-
Price and volume
Market cap
$5.4B
Beta
0.88
52-week high
$163.71
52-week low
$77.10
Average daily volume
1M
Financial strength
Current ratio
6.487
Quick ratio
5.402
Long term debt to equity
13.807
Total debt to equity
13.807
Interest coverage (TTM)
-13.09%
Management effectiveness
Return on assets (TTM)
-6.68%
Return on equity (TTM)
-20.36%
Valuation
Price to revenue (TTM)
12.786
Price to book
7.05
Price to tangible book (TTM)
12.24
Price to free cash flow (TTM)
-97.151
Growth
Revenue change (TTM)
23.92%
Earnings per share change (TTM)
-21.22%
3-year revenue growth (CAGR)
11.26%
3-year earnings per share growth (CAGR)
56.32%
What the Analysts think about Glaukos
Analyst ratings (Buy, Hold, Sell) for Glaukos stock.
Glaukos Financial Performance
Revenues and expenses
Glaukos Earnings Performance
Company profitability
Glaukos News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Glaukos stock?
Glaukos (GKOS) has a market cap of $5.4B as of May 30, 2025.
What is the P/E ratio for Glaukos stock?
The price to earnings (P/E) ratio for Glaukos (GKOS) stock is 0 as of May 30, 2025.
Does Glaukos stock pay dividends?
No, Glaukos (GKOS) stock does not pay dividends to its shareholders as of May 30, 2025.
When is the next Glaukos dividend payment date?
Glaukos (GKOS) stock does not pay dividends to its shareholders.
What is the beta indicator for Glaukos?
Glaukos (GKOS) has a beta rating of 0.88. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.